Precigen Inc (PGEN)
1.02
0.00 (0.00%)
USD |
NASDAQ |
Mar 20, 16:00
1.00
-0.02 (-1.96%)
After-Hours: 20:00
Precigen Gross Profit Margin (Quarterly): 28.70% for Dec. 31, 2022
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2022 | 28.70% |
| September 30, 2022 | 90.57% |
| June 30, 2022 | 37.79% |
| March 31, 2022 | 46.60% |
| December 31, 2021 | 57.08% |
| September 30, 2021 | 56.44% |
| June 30, 2021 | 64.61% |
| March 31, 2021 | 47.06% |
| December 31, 2020 | 28.67% |
| September 30, 2020 | 44.08% |
| June 30, 2020 | 50.99% |
| March 31, 2020 | 54.34% |
| December 31, 2019 | 2.66% |
| September 30, 2019 | 21.00% |
| June 30, 2019 | 49.08% |
| March 31, 2019 | 34.41% |
| December 31, 2018 | 60.04% |
| September 30, 2018 | 52.77% |
| June 30, 2018 | 59.06% |
| Date | Value |
|---|---|
| March 31, 2018 | 61.40% |
| December 31, 2017 | 78.23% |
| September 30, 2017 | 67.37% |
| June 30, 2017 | 69.05% |
| March 31, 2017 | 70.58% |
| December 31, 2016 | 68.78% |
| September 30, 2016 | 69.46% |
| June 30, 2016 | 67.46% |
| March 31, 2016 | 64.93% |
| December 31, 2015 | 63.95% |
| September 30, 2015 | 68.77% |
| June 30, 2015 | 59.31% |
| March 31, 2015 | 58.53% |
| December 31, 2014 | 59.37% |
| September 30, 2014 | 69.15% |
| June 30, 2014 | 99.55% |
| March 31, 2014 | 99.58% |
| December 31, 2013 | 99.69% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
2.66%
Minimum
Dec 2019
90.57%
Maximum
Sep 2022
47.37%
Average
50.03%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Sonoma Pharmaceuticals Inc | 28.23% |
| First Wave BioPharma Inc | -- |
| Baudax Bio Inc | -1.45K% |
| Xilio Therapeutics Inc | -- |
| Abbott Laboratories | 54.48% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 28.00% |
| Return on Assets | 9.49% |
| Return on Invested Capital | 11.69% |
| Profit Margin (Quarterly) | -1.26K% |
| Operating Margin (Quarterly) | -1.24K% |
| Return on Net Operating Assets | 23.31% |